RxDoctor Payments Data

Tami Buzzard

Adult Health · Olean, NYNPI 1528067667

Payments from drug & device makers

$5,558in general payments, 2019–2025

Across 311 payments — averaging $17.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$647
  • Novo Nordisk$510
  • Pfizer$508
  • Merck$457
  • E.r. Squibb & Sons, L.L.C.$403
  • AstraZeneca$387
  • plus $3K from 24 others

What the payments were for

  • Food & beverage$5,544100%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,558 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$41,614
Medicare patients
275
Services billed
517

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban294$286,004
XareltoRivaroxaban100$79,862
EntrestoSacubitril/Valsartan52$53,320
MultaqDronedarone Hcl17$21,008
Repatha SureclickEvolocumab23$20,466
Praluent PenAlirocumab14$15,518
Metoprolol Succinate400$7,121
Ranolazine ErRanolazine50$4,154
Atorvastatin Calcium289$3,404
Rosuvastatin Calcium144$2,597
Ezetimibe114$2,244
Amlodipine Besylate233$1,623
Isosorbide Mononitrate ErIsosorbide Mononitrate123$1,620
Losartan Potassium119$1,298
Lisinopril178$1,232

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$508$286,004294 claims
Johnson & JohnsonXarelto$330$79,862100 claims
NovartisEntresto$647$53,32052 claims
Sanofi-aventis U.S. LLCMultaq$92$21,00817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in Olean

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →